Zambon and US Worldmeds partner to bring Newron Pharmaceuticals’ Parkinson’s disease treatment Xadago® (safinamide) to the U.S.

Milan, Italy – March 17, 2016 – Zambon S.p.A., an international pharmaceutical company strongly committed to the central nervous system (CNS) therapeutic area, today announced a strategic agreement with US WorldMeds to commercialize Newron’s lead compound, Xadago (safinamide), for the treatment of Parkinson’s disease in the U.


Read all

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.